RxDoctor Payments Data

Samuel Boles, MD

Ophthalmology · Annapolis, MDNPI 1255338307

Payments from drug & device makers

$12,566in general payments, 2019–2025

Across 372 payments — averaging $33.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$1K
  • Heru, Inc.$1K
  • Tarsus Pharmaceuticals, Inc.$811
  • Bausch & Lomb Americas Inc.$798
  • Aerie Pharmaceuticals, Inc.$797
  • plus $5K from 28 others

What the payments were for

  • Food & beverage$12,48999%
  • Education$580%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,566 in reported general payments places this provider in the 80th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$924,025
Medicare patients
2,211
Services billed
9,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost325$194,347
RocklatanNetarsudil Mesylat/Latanoprost100$78,389
VyzultaLatanoprostene Bunod96$57,951
RestasisCyclosporine39$47,629
Travoprost138$45,708
XiidraLifitegrast32$44,191
RhopressaNetarsudil Mesylate55$37,639
SimbrinzaBrinzolamide/Brimonidine Tart155$35,740
CombiganBrimonidine Tartrate/Timolol56$29,573
Loteprednol Etabonate131$18,897
Cyclosporine30$17,349
Tobradex StTobramycin/Dexamethasone72$16,369
Travatan ZTravoprost12$14,861
Latanoprost724$10,010
IyuzehLatanoprost/Pf25$9,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$2,471$275,756436 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$797$116,028155 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$798$102,142128 claims
AlconSimbrinza$1,453$35,740155 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$348$18,897131 claims
Eyevance Pharmaceuticals LLCTobradex St$59$16,36972 claims
NovartisTravatan Z$182$14,86112 claims
Thea Pharma Inc.Iyuzeh$221$9,81925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →